Prescription Drug Prices: An AAN Position Statement

Area of Science:

• Neurology
• Health Economics
• Health Policy

Background:

• High prescription drug costs pose challenges for neurological disease therapies.
• Neurologists aim to deliver high-value care at the lowest possible cost.
• Several factors contribute to escalating drug prices, including unjustified increases and high costs for rare disease medications.

Purpose of the Study:

• To establish the American Academy of Neurology's (AAN) position on prescription drug cost-containment strategies.
• To inform policymakers about the AAN's stance on addressing drug pricing.
• To ensure effective prescription medications remain accessible for patients with complex, chronic neurological conditions.

Main Methods:

• The AAN developed a position statement based on an analysis of current drug pricing challenges.
• The statement outlines the AAN's concerns regarding the value proposition of high-cost neurological therapies.
• The AAN considered potential solutions and their impact on patients and the healthcare system.

Main Results:

• Identified three major cost challenges: unjustified price hikes, high costs for rare disease drugs, and high costs for non-innovative therapies.
• Expressed concern that high costs do not always equate to sufficient patient or societal value.
• Highlighted the potential for cost-containment efforts to negatively impact patient and prescriber access if not carefully managed.

Conclusions:

• Action is necessary to ensure access to effective prescription medications for neurological disorders.
• Proposed solutions must be affordable, simple, and transparent.
• The AAN supports strategies including price negotiations, generics/biosimilars, novel therapeutic development, price transparency, and importation.